Novo Nordisk (NVO.US) experiences a near 4% increase as it introduces a new platform to provide weight loss medication services to self-paying patients.

On Wednesday, Novo Nordisk (NVO.US) officially unveiled NovoCare Pharmacy, a new platform designed to provide services for its weight loss drug to self-paying patients, directly challenging Eli Lilly's (LLY.US) direct-to-consumer platform LillyDirect, which was launched last year. As of writing, Novo Nordisk rose nearly 4% to $90.91; Eli Lilly rose over 1% to $920.

Through NovoCare, Novo Nordisk will offer its star weight loss drug Wegovy (semaglutide) to uninsured patients or those with commercial insurance that does not cover obesity treatment. The drug will be available in five doses: 0.25mg, 0.5mg, 1mg, 1.7mg, and 2.4mg.

Novo Nordisk said patients can obtain the GLP-1 class weight loss drug through NovoCare Pharmacy with a cash payment of $499 per month, along with home delivery service.